Cover Image

Quantification of cure for pharmacodynamic models of antimalarial drugs: Deterministic versus stochastic approaches

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Meg K. Tully, Robert J. Commons, Julie A. Simpson, David J. Price
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	British Journal of Clinical Pharmacology
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Use of population pharmacokinetic‐pharmacodynamic modelling to inform antimalarial dose optimization in infants
by: Clifford G. Banda, et al.
Published: (2024)

Personalized parathyroid hormone therapy for hypoparathyroidism: Insights from pharmacokinetic‐pharmacodynamic modelling
by: Maira Visscher, et al.
Published: (2024)

Pharmacokinetic‐pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real‐world data
by: Charlotte M. Thomas, et al.
Published: (2026)

Population kinetic/pharmacodynamic modelling of the haemodynamic effects of cafedrine/theodrenaline (Akrinor) under general anaesthesia
by: Christiane Dings, et al.
Published: (2024)

First‐in‐human safety, tolerability, pharmacokinetics and pilot food‐effect study of the candidate antimalarial compound MMV367
by: Andrea Kuemmerle, et al.
Published: (2025)

Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure
by: Juliane Rascher, et al.
Published: (2024)

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects
by: Marije E. Otto, et al.
Published: (2026)

Oseltamivir drug‐disease modelling in infants with influenza virus infection
by: Kun Wang, et al.
Published: (2026)

Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia
by: Jona Joachim, et al.
Published: (2024)

Pharmacokinetic and pharmacodynamic modelling of continuous erythropoiesis receptor activator in children: A comprehensive analysis and real‐world data validation
by: Samer Mouksassi, et al.
Published: (2025)

Pharmacokinetic–pharmacodynamic modelling in a clinical pilot study of rituximab in multiple sclerosis: Towards personalized dosing interval
by: Trond Trætteberg Serkland, et al.
Published: (2025)

Clinical study of the pharmacokinetics and pharmacodynamics of Xininurad tablets in patients with renal impairment
by: Xiaoni Wang, et al.
Published: (2025)

Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus
by: Hongtao Yu, et al.
Published: (2025)

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach
by: Judith Berres, et al.
Published: (2026)

Population pharmacokinetics and pharmacodynamics of intraperitoneal aerosolized nanoparticle albumin‐bound paclitaxel (nab‐PTX) and metabolites
by: Pieter‐Jan De Sutter, et al.
Published: (2026)

Safety, pharmacokinetics and pharmacodynamics of NXC736, a novel sphingosine‐1‐phosphate receptor modulator
by: Woo Kyung Chung, et al.
Published: (2026)

Pharmacology and relevant drug interactions of metamizole
by: David J. Brinkman, et al.
Published: (2025)

Pharmacokinetics and pharmacodynamics of empagliflozin in paediatric patients aged 10–17 years with type 2 diabetes mellitus
by: Juliane Rascher, et al.
Published: (2025)

Pharmacokinetics, pharmacodynamics and safety of casdatifan, a novel hypoxia‐inducible factor‐2α inhibitor, in healthy participants
by: Mohammad Ghasemi, et al.
Published: (2025)

Safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of HRS‐1893, a cardiac myosin inhibitor, in healthy subjects
by: Kexu Yang, et al.
Published: (2026)

Physiologically‐based pharmacokinetic modelling of uridine 5′‐diphosphoglucorosultransferase (UGT) substrate drugs in pregnant women
by: William Saffaf, et al.
Published: (2026)

Predicting drug–drug interactions between ainuovirine and rifampicin plus isoniazid using PBPK modelling
Published: (2024)

Pharmacokinetics, pharmacodynamics and safety of oral formulation (CG‐750) of ivaltinostat, a histone deacetylase inhibitor, compared to IV formulation (CG‐745)
by: Byungwook Kim, et al.
Published: (2024)

Lack of clinically significant drug–drug interactions between the third‐generation integrase strand transfer inhibitor VH4524184 (VH‐184) and combined oral contraceptives
by: E. Doyle, et al.
Published: (2025)

Development of a generalized pharmacokinetic model to characterize clinical pharmacokinetics of monomethyl auristatin E‐based antibody–drug conjugates
by: Hsuan‐Ping Chang, et al.
Published: (2024)

Probability of pharmacokinetic/pharmacodynamic target attainment for different piperacillin/tazobactam dosing regimens in renally impaired patients in a non‐intensive care unit setting
by: Emma Dohmann, et al.
Published: (2025)

Supratherapeutic drug concentration triggers: A novel data‐driven approach to assess their value for medication safety surveillance in intensive care
by: Anne Paulien Langermans, et al.
Published: (2026)

‘Under pressure’: The role of therapeutic drug monitoring in the treatment of hypertension
by: Jorie Versmissen, et al.
Published: (2024)

A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
by: Jane Knöchel, et al.
Published: (2024)

Removing the physician from the equation: Patient‐controlled, home‐based therapeutic drug self‐monitoring of tacrolimus
by: Marinus Hazenbroek, et al.
Published: (2024)

Gabapentinoids in Ireland 2010 to 2020: An observational study of trends in gabapentinoid prescribing, law enforcement drug seizures and postmortem toxicology
by: Louise Durand, et al.
Published: (2024)

Experience of a nirmatrelvir/ritonavir drug–drug interaction expert advice service
Published: (2024)

Therapeutic drug monitoring—Does it really matter?
by: Hans Lennernäs, et al.
Published: (2024)

A case report highlighting drug–drug interactions between 3 life‐saving treatments: Feminizing hormones, antiretrovirals and antituberculosis drugs
by: Tara Suchak, et al.
Published: (2024)

Therapeutic drug monitoring of dolutegravir in children and adolescents living with HIV: A retrospective study
by: E. Pilote, et al.
Published: (2025)

Economic evaluations of therapeutic drug monitoring interventions in acute hospital‐based settings: A systematic review
by: Jane E. Carland, et al.
Published: (2024)

Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties
by: Geofrey Oteng Phutietsile, et al.
Published: (2024)

Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response
by: Magnus Ingelman‐Sundberg, et al.
Published: (2024)

Dreaming of a cardiovascular drug sanctuary: Why some old drugs still matter
by: Lukas Kloesges, et al.
Published: (2026)

Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach
by: Alexandre Acramel, et al.
Published: (2024)